457 related articles for article (PubMed ID: 9164446)
1. Troglitazone for non-insulin-dependent diabetes mellitus.
Med Lett Drugs Ther; 1997 May; 39(1001):49-51. PubMed ID: 9164446
[No Abstract] [Full Text] [Related]
2. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
3. Effects of troglitazone on insulin sensitivity.
Henry RR
Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
[TBL] [Abstract][Full Text] [Related]
4. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
6. [Clinical results of troglitazone (CS-045)].
Iwamoto Y
Nihon Rinsho; 1997 Nov; 55 Suppl():131-6. PubMed ID: 9434456
[No Abstract] [Full Text] [Related]
7. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
8. Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
Teter ML
Nurse Pract; 1997 Jul; 22(7):119-21. PubMed ID: 9253019
[No Abstract] [Full Text] [Related]
9. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
10. Warner-Lambert voluntarily withdraws Rezulin.
Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
[No Abstract] [Full Text] [Related]
11. Troglitazone.
Spencer CM; Markham A
Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in type 2 diabetes: the role of repaglinide.
Moses R
J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
[No Abstract] [Full Text] [Related]
13. [Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Westerbacka J; Yki-Järvinen H
Duodecim; 1997; 113(19):1847-8. PubMed ID: 10892078
[No Abstract] [Full Text] [Related]
14. New labeling and use changes for Rezulin.
Klonoff DC
Diabetes Technol Ther; 1999; 1(3):350. PubMed ID: 11484719
[No Abstract] [Full Text] [Related]
15. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
Parker JC
Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
17. [Thiazolidindiones in type II diabetes mellitus].
Bornkessel B
Med Monatsschr Pharm; 1998 Mar; 21(3):66-8. PubMed ID: 9556974
[No Abstract] [Full Text] [Related]
18. Troglitazone.
Santiago JV
Compr Ther; 1997 Aug; 23(8):560-2. PubMed ID: 9283746
[No Abstract] [Full Text] [Related]
19. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
[TBL] [Abstract][Full Text] [Related]
20. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
[No Abstract] [Full Text] [Related]
[Next] [New Search]